863 MITTEN ROAD, BURLINGAME, CA
Market cap: $1.7B (2/05/2026)
Price: $20.46
Corvus Pharmaceuticals Enters Underwriting Agreement for Public Offering
Other Events
Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Provides Business Update and Reports Third Quarter 2025 Financial Results
Changes in Board, Management or Compensation
Earnings Release
Shareholder votes
Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload